RxDoctor Payments Data

Mark Kreit, MD

Family Medicine · Cleveland, TXNPI 1083771976

Payments from drug & device makers

$498in general payments, 2019–2025

Across 30 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$134
  • Sunovion Pharmaceuticals Inc.$66
  • Paratek Pharmaceuticals, Inc.$60
  • Sumitomo Pharma America, Inc.$40
  • AbbVie$36
  • Pfizer$32
  • plus $130 from 7 others

What the payments were for

  • Food & beverage$39179%
  • Education$10721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$498 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$98,633
Medicare patients
86
Services billed
9,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide201$264,042
JardianceEmpagliflozin72$93,010
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$85,180
FarxigaDapagliflozin Propanediol82$81,653
EliquisApixaban84$68,778
XifaxanRifaximin19$60,083
TrulicityDulaglutide43$55,608
LinzessLinaclotide69$55,090
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$42,446
Combivent RespimatIpratropium/Albuterol Sulfate49$38,826
Stiolto RespimatTiotropium Br/Olodaterol Hcl36$29,037
GemtesaVibegron31$27,857
MounjaroTirzepatide19$26,036
Spiriva RespimatTiotropium Bromide18$20,192
XareltoRivaroxaban17$20,087

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$16$131,963132 claims
GSKTrelegy Ellipta, Shingrix$27$88,61374 claims
PfizerEliquis$32$68,77884 claims
AbbVieLinzess$36$55,09069 claims
Sumitomo Pharma America, Inc.Gemtesa$40$27,85731 claims
Astellas Pharma US IncMyrbetriq$134$16,68317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Cleveland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →